Head-To-Head Comparison: ProQR Therapeutics (PRQR) vs. Acorda Therapeutics (ACOR)

ProQR Therapeutics (NASDAQ: PRQR) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap bio therapeutic drugs companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for ProQR Therapeutics and Acorda Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics 0 1 3 0 2.75
Acorda Therapeutics 2 9 2 0 2.00

ProQR Therapeutics presently has a consensus target price of $24.00, suggesting a potential upside of 605.88%. Acorda Therapeutics has a consensus target price of $20.58, suggesting a potential downside of 11.47%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Acorda Therapeutics.

Valuation & Earnings

This table compares ProQR Therapeutics and Acorda Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics N/A N/A -$43.27 million ($2.05) -1.66
Acorda Therapeutics $519.60 million 2.09 -$34.61 million ($1.21) -19.21

Acorda Therapeutics has higher revenue and earnings than ProQR Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

31.6% of ProQR Therapeutics shares are owned by institutional investors. 7.9% of Acorda Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

ProQR Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares ProQR Therapeutics and Acorda Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics N/A -97.68% -75.50%
Acorda Therapeutics -10.25% -8.18% -4.15%

Summary

Acorda Therapeutics beats ProQR Therapeutics on 7 of the 13 factors compared between the two stocks.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide, for the treatment of Leber’s congenital amaurosis (LCA), and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

What are top analysts saying about ProQR Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ProQR Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit